ACIP Presentation Slides: June 2018 Meeting

June 20, 2018

Welcome & Introductions

• Welcome and Introductions Cdc-pdf[1 MB, 13 pages]
  Dr. N Bennett
  Dr. A Cohn

 Influenza Vaccines

• Introduction: Influenza Session Cdc-pdf[6 pages]
  Dr. C Walter
• Preliminary Estimates of 2017–18 Seasonal Influenza Vaccine Effectiveness against Laboratory-Confirmed Influenza from the US Flu VE and HAIVEN Networks Cdc-pdf[31 pages]
  Dr. B Flannery
• Relative effectiveness of cell-cultured versus egg-based influenza vaccines, 2017-18 Cdc-pdf[19 pages]
  Dr. Y Lu
• End-of-Season Update: 2017-2018 Influenza Vaccine Safety Monitoring Cdc-pdf[39 pages]
  Dr. T Shimabukuro
• Systematic Observational Method for Narcolepsy and Influenza Immunization Assessment (SOMNIA): a Study to Assess the Risk of Narcolepsy Following Adjuvanted2009 H1N1 Influenza Vaccines Cdc-pdf[27 pages]
  Dr. T Shimabukuro
• Adjuvanted Quadrivalent Influenza vaccine (aQIV) in young children Cdc-pdf[1.2 MB, 21 pages]
  Dr. G Sylvester
• Updates to the 2018-19 Recommendations Cdc-pdf[9 pages]
  Dr. L Grohskopf
• A Thank you to Dr. Nana Bennett Cdc-pdf[1.3 MB, 8 pages]

Anthrax

• Introduction Cdc-pdf[25 pages]
  Dr. W Bower
• GRADE Summary of Work Group considerations and proposed policy options Cdc-pdf[21 pages]
  Dr. W Bower

Human Papilomavirus (HPV) Vaccine

• Human Papillomavirus Vaccines Session Cdc-pdf[6 pages]
  Dr. P Szilagyi
• Background: Application for expanded age indication for 9-valent HPV vaccine Cdc-pdf[19 pages]
  Dr. L Markowitz
• 9vHPV Vaccine for Mid-Adult Persons (27-45 yo) Results from Clinical Studies Cdc-pdf[26 pages]
  Dr. A Luxembourg
• Possible expanded age indication for 9-valent HPV vaccine through age 45 years Cdc-pdf[31 pages]
  Dr. L Markowitz

Update on NITAGS

• Introduction Cdc-pdf[8 pages]
  Dr. A Shefer
• Global NITAG activities and the GNN Cdc-pdf[1.2 MB, 15 pages]
  Dr. J Hombach

Mumps Vaccine

• Advisory Committee on Immunization Practices (ACIP): Mumps Work Group Cdc-pdf[5 pages]
  Dr. K Moore

Zoster Vaccine

• Introduction Cdc-pdf[5 pages]
  Dr. E Belongia
• Herpes Zoster Vaccination: Update Cdc-pdf[21 pages]
  Dr. K Dooling

June 21, 2018

Japanese Encephalitis Vaccine

• Introduction and GRADE for inactivated Vero cell culture-derived JE vaccine (JE-VC) Cdc-pdf[2 MB, 52 pages]
  Dr. C Walter
  Dr. S Hills
• Background for a comparative analysis of JE vaccination strategies for U.S. travelers to Asia Cdc-pdf[10 pages]
  Dr. M Fischer
• Comparative Analysis of Strategies for JE Vaccination for U.S. Travelers to Asia Cdc-pdf[25 pages]
  Dr. S Hills
  Dr. M Meltzer
• Comparative Analysis:Summary and Conclusions Cdc-pdf[9 pages]
  Dr. S Hills

 Pneumococcal

• Introduction Cdc-pdf[13 pages]
  Dr. G Lee
• Safety of PCV13 in adults aged >65 years old Cdc-pdf[32 pages]
  Dr. T Shimabukuro
• Pneumonia Incidence in the US Cdc-pdf[28 pages]
  Dr. A Matanock
• Pneumococcal carriage and disease in Native Americans in the era of routine use of PCV13 Cdc-pdf[31 pages]
  Dr. L Hammitt

Vaccine Supply

• Introduction- Vaccine Supply Update Cdc-pdf[8 pages]
  Dr. J Santoli